The number of people with susceptibility test result for rifampicin in Norway
Norway: The number of people with susceptibility test result for rifampicin was 69 in 2021. ▼ Falling
Latest (2021)
69
Change on year
down 14.8%
World rank
114th
of 155 countries
All-time high
134
in 2017
All-time low
69
in 2021
Years of data
5
2017–2021
The number of people with susceptibility test result for rifampicin in Norway, 2017–2021
Source: World Health Organization, Global Health Observatory.
Analysis
In 2021, the number of people with susceptibility test result for rifampicin in Norway stood at 69. That is the lowest value across all 5 years on record.
That represents a change of down 14.8% on the previous year and down 48.5% over five years.
That places Norway 114th out of 155 countries with data for 2021, putting it in the middle of the range.
The number of people with susceptibility test result for rifampicin in Norway, year by year
| Year | Value | Change |
|---|---|---|
| 2017 | 134 | — |
| 2018 | 100 | -25.4% |
| 2019 | 82 | -18.0% |
| 2020 | 81 | -1.2% |
| 2021 | 69 | -14.8% |
Norway compared with similar countries
- Norway's 69 is below the median for high income countries, which is 142, 49% of the median. (61 countries reporting)
- Norway's 69 is below the median for Europe & Central Asia, which is 229.5, 30% of the median. (44 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 105.33 | 82 | 134 | 3 |
| 2020s | 75 | 69 | 81 | 2 |
Countries ranked near Norway
More health data for Norway
- Un projection of annual infant deaths, annual growth rate -7.69 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.337 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,212 deaths per 1,000 people (2090)
- Number of infants who die before age 1 12 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2021)
- Population ages 00-04, female, annual growth rate -0.217 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0238 units per person (2025)
- Population ages 00-04, male, annual growth rate -0.0617 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is the number of people with susceptibility test result for rifampicin in Norway?
- The number of people with susceptibility test result for rifampicin in Norway was 69 in 2021, according to World Health Organization, Global Health Observatory.
- What is the highest the number of people with susceptibility test result for rifampicin recorded in Norway?
- The highest recorded value was 134 in 2017.
- What is the lowest the number of people with susceptibility test result for rifampicin recorded in Norway?
- The lowest recorded value was 69 in 2021.
- How does Norway rank for the number of people with susceptibility test result for rifampicin?
- Norway ranks 114th out of 155 countries with data for 2021.
- Where does this Norway data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 5 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).